MARKET

KDMN

KDMN

KADMON
NYSE

Real-time Quotes | Nasdaq Last Sale

3.860
-0.210
-5.16%
Closed 17:10 04/02 EDT
OPEN
4.020
PREV CLOSE
4.070
HIGH
4.100
LOW
3.590
VOLUME
1.27M
TURNOVER
--
52 WEEK HIGH
5.50
52 WEEK LOW
1.630
MARKET CAP
616.69M
P/E (TTM)
-7.9719
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KDMN stock price target is 13.25 with a high estimate of 25.00 and a low estimate of 8.00.

EPS

KDMN News

More
  • Kadmon Holdings: Pick Up This Late-Stage Biopharmaceutical Company In March 2020
  • Seeking Alpha - Article · 03/14 16:04
  • Kadmon Announces Update on pre-NDA Meeting with FDA and Provides Business Update
  • ACCESSWIRE · 03/13 21:15
  • Here's Why We're Not Too Worried About Kadmon Holdings's (NYSE:KDMN) Cash Burn Situation
  • Simply Wall St. · 03/09 18:57
  • Kadmon Holdings Q4 EPS $(0.09) Up From $(0.37) YoY, Sales $256K Up From $232K YoY
  • Benzinga · 03/05 21:16

Industry

Pharmaceuticals
+2.64%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About KDMN

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
More

Webull offers kinds of Kadmon Holdings Inc stock information, including NYSE:KDMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KDMN stock news, and many more online research tools to help you make informed decisions.